

## **Varicella zoster virus encephalitis**

By Prav Prathapan, Encephalitis International, and reviewed by Dr Sylviane Defres, Consultant Infectious diseases, Tropical and Infectious diseases Unit, Liverpool University Hospitals Foundation NHS Trust, Liverpool School Tropical Medicine and Institute of Infection Veterinary and Ecological Sciences , University of Liverpool

### **What is Varicella zoster virus (VZV) encephalitis?**

VZV encephalitis refers to a neurological complication associated with the Varicella-zoster virus (VZV), which can cause varicella (chickenpox) during primary infection and herpes zoster (shingles) upon reactivation. While VZV infections are common, encephalitis occurs more rarely, with an estimated incidence of 1 per 30,000 – 50,000 varicella cases. This condition can affect adults and infants and is more common and more severe in those who are immunocompromised.

### **Symptoms**

Neurological signs: patients with VZV encephalitis may present with symptoms such as headache, fever, vomiting, seizures, sensory changes, and altered levels of consciousness. Symptoms may be subtle with change in personality or cognition also being presenting features.

Motor abnormalities: ataxia (loss of coordination), hypertonia or hypotonia (increased or decreased muscle tone), hyperreflexia or hyporeflexia (increased or decreased reflexes), and hemiparesis (muscle weakness on one side of the body) are also possible.

Rash presence: although encephalitis often occurs alongside the characteristic rash of chickenpox or shingles, it can also manifest without this rash. There may have been a rash in preceding few months prior to developing encephalitis.

### **Diagnosis**

Diagnosing VZV encephalitis involves a combination of clinical assessment and diagnostic tests. Detection of VZV DNA in the central spinal fluid (CSF) is a key diagnostic method. Though it is only detected in about a third of the time. Antibody testing in the CSF may be necessary. Other laboratory tests may be performed to rule out other potential causes of encephalitis. Neuroimaging using EEG and MRI scans may identify abnormalities in brain activity and structure.

### **Treatment**

Aciclovir, a potent antiviral drug, is the primary treatment for VZV encephalitis. Administering aciclovir early can help reduce the severity and duration of the illness. Patients may require supportive measures, including hydration and management of symptoms such as fever and seizures.

### **Outcomes**

The outcomes of VZV encephalitis vary widely, ranging from complete recovery to various degrees of residual effects. Mortality rates range from 5% to 15%, highlighting the seriousness of this condition. Patients who survive may experience long-term neurological consequences, including cognitive impairment, motor deficits, and seizures.

## Prevention

Vaccination against varicella (to prevent primary chickenpox infection) has been integrated into national immunization programs in numerous countries. Proper vaccination can prevent varicella and subsequently reduce the risk of VZV encephalitis. Practicing good hygiene and avoiding contact with individuals experiencing active VZV infections can help prevent transmission to individuals susceptible to VZV infection. Two shingles vaccines are available to prevent reactivation of the VZV virus and are available from the age of 65 years in the UK, or from 50 years for those with weakened immune systems.

In conclusion, VZV encephalitis is a rare but serious neurological complication associated with VZV infections. Timely diagnosis, appropriate treatment, and prevention measures, such as vaccination and public awareness, play essential roles in managing this condition and reducing its impact on individuals' health and well-being.

---

## FS070V1 Varicella zoster virus encephalitis

Date created: August 2023 / Last updated: March 2024 / Review date: March 2027

Disclaimer: We try to ensure that the information is easy to understand, accurate and up to date as possible. If you would like more information on the source material and references the author used to write this document, please contact Encephalitis International. None of the authors of the above document has declared any conflict of interest, which may arise from being named as an author of this document.

---

## Support our information

With our support, no one has to face encephalitis alone. Our advice and information are available free of charge to everyone affected but we are truly grateful when supporters feel able to contribute a little to the cost of these resources. Please donate today by visiting [www.encephalitis.info/donate](http://www.encephalitis.info/donate) or text the word DOCTOR to 70085 to donate £5.

## Thank you!

---

**Encephalitis International**, 32 Castlegate, Malton, North Yorkshire, YO17 7DT, UK

**Administration:** +44 (0) 1653 692583 **Support:** +44 (0) 1653 699599

**Email:** [mail@encephalitis.info](mailto:mail@encephalitis.info) **Website:** [www.encephalitis.info](http://www.encephalitis.info)

Encephalitis International is the operating name of the Encephalitis Support Group.

Registered Charity England and Wales No: 1087843; Registered Charity in Scotland No: SC048210

Charitable Company registered in England and Wales No: 04189027